Wyeth Provides Regulatory Update Regarding Desvenlafaxine for the Treatment of Major Depressive Disorder

Collegeville, Pennsylvania (ots/PRNewswire) -

- Company Underscores Commitment to Availability in Worldwide
Markets

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today
provided an update on its global strategy for desvenlafaxine for the
treatment of major depressive disorder (MDD) in adults.

Desvenlafaxine has already been approved for the treatment of MDD
in adults in the United States, Australia and Brazil, and
applications are currently pending in 22 markets. As part of its
global regulatory strategy, and in consultation with the Committee
for Medicinal Products for Human Use of the European Medicines
Agency, the Company has chosen not to pursue its central European
Marketing Authorisation Application at this time. Wyeth remains
committed to making desvenlafaxine available to patients with MDD
around the world, including in Europe. It is available in the United
States under the name PRISTIQ.

"We are considering a number of options to support depressed
patients and their families," says Gary L. Stiles, M.D., Executive
Vice President and Chief Medical Officer. "There are millions of
patients with depression, and clearly more treatments are necessary."

Wyeth has a long history of innovation in neuroscience. In 1993,
the Company introduced the first serotonin-norepinephrine reuptake
inhibitor, which has been prescribed to millions of people worldwide.
Building on this research platform, desvenlafaxine represents Wyeth's
newest antidepressant therapy.

About Wyeth Pharmaceuticals

Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies. It is a leader in
the discovery, development, manufacturing and marketing of
pharmaceuticals, vaccines, biotechnology products and
non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.

The statements in this press release that are not historical
facts are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, without limitation, the inherent uncertainty
of the timing and success of, and expense associated with, research,
development, regulatory approval and commercialization of our
products and pipeline products (including future regulatory action
regarding our pending applications in other countries for
desvenlafaxine for the treatment of major depressive disorder and the
treatment of vasomotor symptoms, as to which no assurance can be
given); government cost-containment initiatives; restrictions on
third-party payments for our products; substantial competition in our
industry, including from branded and generic products; emerging data
on our products and pipeline products; the importance of strong
performance from our principal products and our anticipated new
product introductions; the highly regulated nature of our business;
product liability, intellectual property and other litigation risks
and environmental liabilities; uncertainty regarding our intellectual
property rights and those of others; difficulties associated with,
and regulatory compliance with respect to, manufacturing of our
products; risks associated with our strategic relationships; economic
conditions including interest and currency exchange rate
fluctuations; changes in generally accepted accounting principles;
trade buying patterns; the impact of legislation and regulatory
compliance; risks and uncertainties associated with global operations
and sales; and other risks and uncertainties, including those
detailed from time to time in our periodic reports filed with the
Securities and Exchange Commission, including our current reports on
Form 8-K, quarterly reports on Form 10-Q and annual report on Form
10-K, particularly the discussion under the caption "Item 1A, RISK
FACTORS" in our Annual Report on Form 10-K for the year ended
December 31, 2007, which was filed with the Securities and Exchange
Commission on February 29, 2008. The forward-looking statements in
this press release are qualified by these risk factors. We assume no
obligation to publicly update any forward-looking statements, whether
as a result of new information, future developments or otherwise.

ots Originaltext: Wyeth Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media: Gwen Fisher of Wyeth Pharmaceuticals, +1-484-865-5160, or
Douglas Petkus of Wyeth, +1-973-660-5218, or Investor Contact:
Justin Victoria of Wyeth, +1-973-660-5340